Interchange of vaccine products; Revaccination with different COVID-19 vaccine; No Adverse Event; SARS-CoV-2 IgG antibody test; This spontaneous case was reported by a patient and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products), COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine), NO ADVERSE EVENT (No Adverse Event) and SARS-COV-2 ANTIBODY TEST NEGATIVE (SARS-CoV-2 IgG antibody test) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for an unknown indication.    The patient had not taken the vaccine as patient had no B-cells because she was taking Rituxan for chemo. The patient had stopped taken Rituxan since Sep 2020. Rituxan wiped patient's B-cells out, and patient doesn't had anything.  The patient's past medical history included Chemotherapy (she has no B-cells because she was taking Rituxan for chemo). Concurrent medical conditions included Diabetes since 1995, Neuropathy (Terrible Neuropathy which  began in 2004, but was not sure. Clarified that began early 2000s.) and High cholesterol since 1995. Concomitant products included PREGABALIN (LYRICA) for Neuropathy.   On 02-Mar-2021 at 11:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Mar-2021 at 11:00 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-May-2021 at 2:00 PM, the patient received first dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. On 02-Jun-2021 at 2:00 PM, received second dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products), COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine), NO ADVERSE EVENT (No Adverse Event) and SARS-COV-2 ANTIBODY TEST NEGATIVE (SARS-CoV-2 IgG antibody test). At the time of the report, INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products), COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine), NO ADVERSE EVENT (No Adverse Event) and SARS-COV-2 ANTIBODY TEST NEGATIVE (SARS-CoV-2 IgG antibody test) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 28-Apr-2021, SARS-CoV-2 antibody test: (Negative) Negative for monoclonal antibodies. On 23-Jun-2021, SARS-CoV-2 antibody test: (Negative) Negative for monoclonal antibodies.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) and NO ADVERSE EVENT (No Adverse Event) to be not related. No further causality assessments were provided for COVID-19 IMMUNISATION (Revaccination with different COVID-19 vaccine) and SARS-COV-2 ANTIBODY TEST NEGATIVE (SARS-CoV-2 IgG antibody test).      Lyrica was patient's lifesaver. Would be crippled without Lyrica and also stated Lyrica was a wonderful medication. The patient stated neuropathy used to just be in patient's feet. Now was  in patient's hands as well. Began feeling neuropathy in hands four years ago. The patient had not visited emergency room and physician office, patient stated was already at her oncologist when that was figure out. The patient was not sick at time of vaccinations.  No treatment medication were provided.  This case was identified as part of a retrospective clean-up activity where certain emails received in the moderna mailbox were missed to be booked-in.